학술논문

PD-0152 Radiation-induced lymphopenia risk model predicts durvalumab benefit in non-small cell lung cancer.
Document Type
Abstract
Source
In Radiotherapy and Oncology May 2023 182 Supplement 1:S113-S114
Subject
Language
ISSN
0167-8140